VRNA - Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023 | Benzinga

LONDON and RALEIGH, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), announces an oral presentation on an additional analysis from its successful Phase 3 ENHANCE-1 study with ensifentrine for the treatment of chronic obstructive pulmonary disease ("COPD") will be presented at the European Respiratory Society ("ERS") International Congress 2023. The abstract is available to conference attendees on the ERS website and will be published in an upcoming issue of the peer reviewed publication, European Respiratory Journal.

The presentation will highlight additional analyses of the ENHANCE-1 24-week exacerbation data which demonstrated treatment with ensifentrine resulted in a substantial decrease in the rate and risk of moderate COPD exacerbations as well as moderate and severe COPD exacerbations. Furthermore, it will highlight the impact of ensifentrine treatment on healthcare resource utilization related to COPD including fewer physician's office visits, emergency department visits and hospitalizations compared with placebo treatment.

Henrik Watz, MD, Respiratory Physician at The Pulmonary Research Institute at LungenClinic Grosshansdorf, Germany, commented: "This exciting analysis from the ENHANCE-1 study further demonstrates ensifentrine's potential to become a first-in-class bronchodilator and non-steroidal anti-inflammatory therapy for COPD. The reduction in the rate and risk of exacerbations is impressive and, combined with the data showing substantial reductions in healthcare resource utilization, these data support ensifentrine's potential, if approved, to provide meaningful benefits for COPD patients."

Details of Verona Pharma's presentation are listed below and linked to the ERS website:

Oral presentation 2602: Inhaled Ensifentrine, decreased healthcare research utilization and reduced moderate exacerbation rate and risk in COPD over 24 weeks
Participant: Henrik Watz, MD, Pulmonary Research Institute at LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany.
Session 269: New mechanisms and novel insights into chronic obstructive pulmonary disease and chronic cough

For further information please contact:

Full story available on Benzinga.com